Stroke-treatment startup Imperative Care (Campbell, Calif.) said it has landed FDA approval for its first line of access catheters.
Access to brain blood vessels can be challenging because of the brain’s highly complex and twisted vascular structure. The catheters were designed to deliver interventional treatments during minimally invasive neurovascular procedures for aneurysms, stroke, and other brain blood-vessel conditions, the company said.
“Recognizing the significant need to elevate the standard of patient therapeutics in stroke, Imperative Care was founded to become the comprehensive stroke company innovating across the entire continuum of care,” said Imperative Care founding chairman and CEO Fred Khosravi in a prepared statement. “Our approach is informed by a unique clinical perspective, along with a keen appreciation that this underserved medical category requires a holistic commitment and focus to make better stroke treatment modalities available to more patients around the world.”
Imperative Care is the 21st company co-founded by Incept, a medtech accelerator and development company.
Modern imaging modalities, therapeutic technologies and clinical rigor in identifying the importance of timing and intervention in stroke care have revolutionized its treatment, added L. Nelson Hopkins, M.D., Imperative Care co-founder and chief scientific officer of the Jacobs Institute in Buffalo, N.Y.
“All of these important advancements have underscored that, as in the treatment of acute myocardial infarctions, improved mechanical solutions to physically open the blocked brain artery will continue to offer clear advantages for improved patient outcomes,” Hopkins said. “Stroke no longer has to be a death or disability sentence. With new technologies, more patients will be able to return to normal lives following a stroke.”
Imperative Care said it is also developing a pipeline of technologies designed to help clinicians improve the effectiveness and speed of acute stroke treatment, with the goal of enabling better patient outcomes. The company’s near-term pipeline includes an aspiration treatment catheter designed to enable rapid clot removal.